Bevacizumab in epithelioid hemangioendothelioma.
| Author | Reference | Age (years) | Gender (M/F) | Dose and schedule | Chemotherapy | Outcome | Follow-up |
|---|---|---|---|---|---|---|---|
| Belmont et al. | 5 | 41 | M | 15 mg/kg, every 21 days | Carboplatin, paclitaxel, docetaxel | Partial response | 13 months |
| Kim YH et al. | 6 | 44 | F | 15 mg/kg, every 21 days | Carboplatin,paclitaxel | Progression | |
| Mizota et al. | 7 | 59 | F | 15 mg/kg, every 21 days | Carboplatin, paclitaxel | Progression | 3 months |
| Lazarus et al. | 8 | 42 | M | ? | Paclitaxel | Progression | 1-2 months |
| Lazarus et al. | 8 | 42 | M | ? | Carboplatin, etoposide | Progression | 2-3 months |
| Trautmann et al. | 9 | 19 | F | 7.5 mg/m2, every 21 days | None | Stable disease | 16 months |